Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer.

Patients with grade 2/3 neutropenia were significantly younger (mean age 48 years) than those with grade 4 neutropenia (mean age 52 years, P <0.002), and overall there was a significant trend for higher grades of neutropenia in older patients ( χ 2 for trend=6.87, P <0.01).

also in 5,329 other papers

There is an apparent trend for a lower incidence of neutropenia in later courses, with, for example, 4% following the first course, 3% after the fourth and only 1% in the final course ( χ 2 for trend across all six cycles=16, P <0.001).

also in 323 other papers